Report Adverse Event or Product Quality Complaint   US Site   Global Site             

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ESCMID 2026

Congress of the European Society of Clinical Microbiology and Infectious Diseases
(ESCMID Global) - 2026

April 17 - 21, 2026

  1. All
  2. IVX-A12
  3. Gremubamab

PDF

Incidence of hMPV and RSV among hospitalized adults in the US during the 2024-2025 respiratory season: interim results from the ARIA study

PDF

Incidence of human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) among adults 50 years and older in the outpatient setting in the US: interim results from the ARIA study

PDF

Hospitalisation costs associated with hMPV versus RSV infection in adults

HTML

Pathogen-specific viral infections among adults hospitalised with severe acute respiratory infection: European multicentre surveillance study, 2024-2025 (id.DRIVE)

PDF

The long-term burden of hospitalized Immunocompromised Individuals for Respiratory Viruses infections

PDF

Aetiology and symptoms associated with acute respiratory infections across healthcare settings in older adults in Valencia, Spain: a preliminary analysis of the prospective VIRIN study

PDF

Safety, efficacy and immunological effects of a bispecific monoclonal antibody targeting Pseudomonas aeruginosa in bronchiectasis: Results from the GREAT-2 trial

PDF

Incidence of hMPV and RSV among hospitalized adults in the US during the 2024-2025 respiratory season: interim results from the ARIA study

PDF

Incidence of human metapneumovirus (hMPV) and respiratory syncytial virus (RSV) among adults 50 years and older in the outpatient setting in the US: interim results from the ARIA study

PDF

Hospitalisation costs associated with hMPV versus RSV infection in adults

HTML

Pathogen-specific viral infections among adults hospitalised with severe acute respiratory infection: European multicentre surveillance study, 2024-2025 (id.DRIVE)

PDF

The long-term burden of hospitalized Immunocompromised Individuals for Respiratory Viruses infections

PDF

Aetiology and symptoms associated with acute respiratory infections across healthcare settings in older adults in Valencia, Spain: a preliminary analysis of the prospective VIRIN study

PDF

Safety, efficacy and immunological effects of a bispecific monoclonal antibody targeting Pseudomonas aeruginosa in bronchiectasis: Results from the GREAT-2 trial

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-107328
Last Updated 5/26

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States